Citation: Carr A, Ory D (2006) Does HIV Cause Cardiovascular Disease? PLoS Med 3(11): e496. https://doi.org/10.1371/journal.pmed.0030496
Published: November 28, 2006
Copyright: © 2006 Carr and Ory. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors received no specific funding for this article.
Competing interests: AC has received research grants or funding from Abbott, Boehringer Ingelheim, and Roche; consultancy fees from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, and Roche; lecture sponsorships from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, and GlaxoSmithKline; and has served on advisory boards for Bristol-Myers Squibb, GlaxoSmithKline, and Roche. DO has received research grants or funding from Pfizer, and consultancy fees from Merck and GlaxoSmithKline.
Abbreviations: ART, antiretroviral therapy; HDL, high-density lipoprotein; LXR, liver X receptor
HIV, Antiretroviral Therapy, and Cardiovascular Disease
Cardiovascular disease is an increasing cause of morbidity in HIV-infected adults receiving antiretroviral therapy (ART). ART, particularly protease inhibitors and to a lesser extent nucleoside analogue reverse transcriptase inhibitors, can adversely affect lipid and glucose metabolism . Moreover, there is a strong correlation between ART duration and the risk of myocardial infarction, an association in part linked to higher plasma levels of total cholesterol and triglyceride and to lower levels of high-density lipoprotein (HDL) cholesterol . Paradoxically, interruption of ART also appears to be associated with an increased short-term risk of cardiovascular disease . These findings suggest that HIV itself may also increase cardiovascular risk, and that control of HIV replication might reduce this risk.
HDL cholesterol levels are reduced in untreated HIV infection  and in healthy volunteers exposed for a short term to the HIV protease inhibitors ritonavir-boosted atazanavir and lopinavir [5,6]. In HIV-infected individuals who start ART that effectively suppresses HIV replication, HDL cholesterol levels increase, regardless of whether a protease inhibitor is used [7–9], implying that the HIV effect on HDL cholesterol levels is greater than the ART effect.
How Does HIV Lower HDL Cholesterol Levels?
The pathogenesis of low HDL cholesterol levels in untreated HIV infection is unknown. In a study recently published in PLoS Biology, Mujawar et al. investigated whether these lower levels might be due to impaired cholesterol efflux from macrophages , a process mediated by the ABCA1 cell-surface cholesterol transporter. ABCA1 lipidates apoA-I, the major apolipoprotein in HDL, and thus plays a central role in formation of nascent HDL. Mutations in ABCA1 cause Tangier disease, which is associated with low HDL cholesterol and accelerated atherosclerosis .
The researchers found that expression of HIV nef, a protein that enhances HIV replication and infectivity, specifically inhibited ABCA1-dependent cholesterol efflux from macrophages (the precursors of foam cells in atherosclerotic plaque) and re-localized ABCA1 to an exclusive plasma membrane distribution. While nef-transfected cells exhibited increased apoA-I binding, apoA-I internalization was blocked, suggesting that nef at the plasma membrane may prevent ABCA1 internalization and subsequent apoA-I lipidation. As cholesterol is required for HIV replication , Mujawar et al. next examined whether enhancing cholesterol efflux from HIV-infected macrophages affected HIV replication. Using a liver X receptor (LXR) agonist to transcriptionally upregulate ABCA1, cholesterol efflux was augmented, significantly reducing virion-associated cholesterol and infectivity.
There is a strong correlation between ART duration and the risk of myocardial infarction.
What Do the Findings Mean?
Mujawar et al. propose that HIV nef redirects cholesterol from an ABCA1-mediated efflux pathway to virus-controlled cholesterol transport in order to ensure sufficient cholesterol for virion assembly. The interruption of a host cholesterol trafficking pathway by an intracellular pathogen is also employed by Toxoplasma gondii, in which endocytosed low-density lipoprotein cholesterol is diverted to a specialized vacuole to support parasite growth and replication . Given that impaired ABCA1 function results in decreased HDL cholesterol and accelerated atherosclerosis , the findings of Mujawar et al. provide a possible mechanism to explain low HDL cholesterol in HIV infection and increased cardiovascular risk in HIV-infected adults.
It remains to be determined, however, if this mechanism is the greatest contributor to these low levels. If so, one would expect that HDL cholesterol levels would fall rapidly after primary HIV infection and return to pre-infection levels with effective ART that did not affect lipid metabolism. In addition, the observed reductions might be inversely proportionate to plasma HIV RNA levels. Alternatively, low HDL cholesterol levels may also be caused by ART-induced lipodystrophy. This ART side effect is characterized by peripheral lipoatrophy and relative central adiposity and is strongly associated with low HDL cholesterol levels as well as insulin resistance and hypertriglyceridemia, all features of congenital lipodystrophies in which abnormalities of ABCA1 have not been identified [2,15,16].
The Strengths and Limitations of the Study
The findings of Mujawar et al. raise several important questions. Is the apparent nef-stimulated decrease in ABCA1 protein levels due to ABCA1 degradation, or possibly due to altered partitioning of ABCA1 into detergent-resistant lipid domains? Does nef physically interact with ABCA1? Use of the myristoylation-deficient nef in this study only suggests that nef must be targeted to the plasma membrane—likely to cholesterol rafts . Furthermore, experiments involving immunoprecipitation of raft-associated proteins must be interpreted with caution, and should be followed up with more rigorous studies (e.g., identification of interaction domains and fluorescence resonance energy transfer) that provide support for a specific ABCA1–nef interaction at the plasma membrane. Finally, might LXR ligands activate target genes, other than ABCA1, that could attenuate virion-associated cholesterol? Treatment of HIV-infected ABCA1-deficient macrophages with LXR ligands should establish a definitive role for ABCA1 in countering HIV replication.
Where To From Here?
The present data provide a clue as to why HIV infection, as well as ART, might accelerate atherosclerosis. The data support the shift away from a paradigm of delaying or stopping ART to reduce the risk of cardiovascular disease and raise the possibility that antiretroviral drugs without direct metabolic effects may actually reduce cardiovascular risk. The data also emphasize the need for clinicians to consider all the metabolic effects (in particular the ratio of total cholesterol to HDL) of each antiretroviral drug, not just total cholesterol levels, in the management of cardiovascular risk in HIV-infected adults.
The study by Mujawar et al. also has important implications for developing new approaches for suppression of HIV replication. Selective LXR modulators under active development for treatment of atherosclerosis may prove useful as ART.
The long-term effects of each antiretroviral drug on HDL cholesterol, as well as other lipid and glycemic parameters, need to be more completely analyzed in randomized trials, as well as in shorter healthy volunteer studies. It remains to be determined whether new antiretroviral drug classes, such as HIV fusion, CCR5, and integrase inhibitors, will be free of these metabolic complications.
- 1. Grinspoon SK, Carr A (2005) Cardiovascular risk and body fat abnormalities in HIV-infected adults. N Engl J Med 352: 48–62.
- 2. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993–2003.
- 3. El-Sadr W, Neaton J (2006) Episodic CD4-guided use of ART is inferior to continuous therapy: Results of the SMART study [abstract]. 13th Conference on Retroviruses and Opportunistic Infections; 5–8 February 2006; Denver, Colorado, United States of America. Available: http://www.retroconference.org/2006/Abstracts/28085.HTM. Accessed 19 October 2006.
- 4. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, et al. (1992) Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74: 1045–1052.
- 5. Noor MA, Flint OP, Parker RA, Maa J, Witek J (2005) Evaluation of insulin sensitivity in healthy volunteers treated with low-dose ritonavir combined with atazanavir (ATV/RTV) or lopinavir (LPV/RTV): A prospective, randomised study using hyperinsulinemic, euglycemic clamp and oral glucose tolerance testing [abstract]. 7th International Workshop on Adverse Events and Lipodystrophy in HIV; 13–16 November 2005; Dublin, Ireland.
- 6. Shafran SD, Mashinter LD, Roberts SE (2005) The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 6: 421–425.
- 7. Malan N, Krantz E, David N, Kastango K, Frederick D, et al. (2006) Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 [abstract]. 13th Conference on Retroviruses and Opportunistic Infections; 5–8 February 2006; Denver, Colorado, United States of America. Available: http://www.retroconference.org/2006/Abstracts/27965.htm. Accessed 19 October 2006.
- 8. Johnson MA, Gathe JC Jr, Podzamczer D, Molina JM, Naylor CT, et al. (2006) A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 43: 153–160.
- 9. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, et al. (2001) Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15: 2407–2414.
- 10. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, et al. (2006) Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 4: e365.
- 11. Oram JF, Lawn RM (2001) ABCA1: The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 42: 1173–1179.
- 12. Liao Z, Graham DR, Hildreth JE (2003) Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res Hum Retroviruses 19: 675–687.
- 13. Coppens I, Sinai AP, Joiner KA (2000) Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition. J Cell Biol 149: 167–180.
- 14. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, et al. (2002) Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 22: 630–637.
- 15. Carr A, Emery SE, Law M, Puls R, Lundgren JD, et al. (2003) An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 361: 726–735.
- 16. Garg A (2004) Acquired and inherited lipodystrophies. N Engl J Med 350: 1220–1234.
- 17. Wang JK, Kiyokawa E, Verdin E, Trono D (2000) The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A 97: 394–399.